VaxInnate's Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study
Study validates proprietary technology that could transform flu vaccine production
A universal flu vaccine candidate that could end the need for annual flu shots and provide protection against seasonal and pandemic flu strains was well tolerated and immunogenic in a Phase I study that was presented at the joint 48th ICAAC/46th IDSA annual meetings. This first clinical study of VaxInnate’s M2e universal flu vaccine candidate also validates company’s novel approach to developing and producing flu vaccines, which is based upon a proprietary combination of toll-like receptor (TLR)-mediated immune enhancement and recombinant bacterial production of vaccine antigen.
“VaxInnate’s M2e universal flu vaccine candidate has passed a critical initial test,” said David Taylor, MD, Chief Medical Officer. “We’re encouraged by these data, which demonstrate that the vaccine is safe and elicits potent immune responses at doses below a microgram of vaccine antigen, and does so without the use of conventional adjuvants.”
The multicenter, double-blind, randomized, placebo-controlled Phase I study was designed to assess the safety and immunogenicity of four doses of the vaccine candidate. The vaccine candidate is comprised of the ectodomain of the viral M2 protein (M2e) fused to the bacterial protein flagellin.
Other news from the department research and development
